Acute Myeloid Leukemia With Inv(16)(p13q22) Associated With Hidden Systemic Mastocytosis: Case Report and Review of Literature. Issue 10 (22nd March 2017)

• Record Type: Journal Article
• Authors: Hilmi, Feryal Abbas Ibrahim; Al-Sabbagh, Ahmad; Soliman, Dina Sameh; Sabah, Hesham Al; Ismail, Omar Mohammad; Yassin, Mohamed; El-Omri, Halima
• Is Part Of: Clinical medicine insights. Issue 10(2017)
• Publication Date: 2017-03-22
• Subjects: Systemic mastocytosis -- acute myeloid leukemia with inv(16)(p13q22) -- KIT mutation; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; Hematologic Diseases; Blood -- Diseases; Hematology; Electronic journals; Periodicals; Fulltext; Internet Resources; Periodicals; Periodicals; 616.15
• DOI: 10.1177/1179545X17700858
• Languages: English
• ISSNs: 1179-545X

Abstract

Systemic mastocytosis (SM) is a condition associated with clonal neoplastic proliferation of mast cells. In up to 40% of systemic mastocytosis cases, an associated clonal hematological disease of non–mast cell lineage, such as acute myeloid leukemia (AML), is diagnosed before, simultaneously with, or after the diagnosis of SM. Herein, we report a case of a 30-year-old man diagnosed with AML with inv(16)(p13;q22) CBFB:MYH11. Associated mastocytosis was not noted at diagnosis and was only detected in the bone marrow at time of remission after successful chemotherapy. The diagnosis of mastocytosis was based on the demonstration of a multifocal dense mast cell infiltrate in the marrow biopsy with aberrant immunophenotype, with coexpression of tryptase, CD117, and CD25. The mast cells showed atypical morphology mostly with irregular nuclear contour, bilobed or multilobed nuclei with cytoplasmic hypogranulation or irregular metachromatic granule distribution, and some cells with eccentric nucleus or spindle shape. Reexamination of the pretherapeutic bone marrow with immunostain for tryptase and CD25 revealed that mastocytosis was present from the start but masked by extensive blast proliferation. This case indicates that mast cell infiltrates are sometimes underappreciated at the original diagnosis of AML with inv(16) and that the concurrent diagnosis of SM with AML requires a high index of suspicion supported with comprehensive morphologic and immunohistochemical evaluation for a neoplastic mast cell proliferation.